Conversations
In vivo CRISPR therapy’s effects persist for four years; FDA expected to decide on approval by next March
Intellia Therapeutics released data saying its in vivo CRISPR-Cas9 therapy lonvoguran ziclumeran remains effective four years after treatment. The therapy is used for a form of hereditary angioedema and can turn off the gene that makes prekallikrein in the liver. If approved by the FDA, it would become the first CRISPR medicine edited directly inside a patient’s body.
Lonvoguran ziclumeran, or lonvo-z for short, targets a form of hereditary angioedema that causes painful and potentially dangerous swelling in the throat and other parts of the body. The therapy uses CRISPR-Cas9 to turn off the gene in the liver that produces prekallikrein, a protein that promotes blood-vessel leakage. Developer Intellia has submitted an approval application to the U.S. Food and Drug Administration, and the FDA is expected to make a decision by March 10 next year.
Chief Executive John Leonard told investors on November 12 that, if approved, lonvo-z would become the world’s first CRISPR medicine delivered directly into the body. The only CRISPR therapy currently approved by the FDA is Casgevy, for sickle cell disease and beta thalassemia; its process first requires removing a patient’s blood-forming stem cells, editing them outside the body, and then infusing them back.
Ex vivo cell therapies must be manufactured separately for each patient, and patients must also undergo strong chemotherapy to make room for the edited cells, adding time, cost, and complexity. Lonvo-z instead wraps mRNA encoding CRISPR-Cas9 components in lipid particles, which are infused through the bloodstream and taken up by the liver; the entire procedure takes about a day.
However, in vivo editing also means cells with unintended edits cannot be screened out before infusion, and patients may have immune reactions. Last year, two in vivo trials by Intellia for another disease were placed under an FDA clinical hold after a participant who had other underlying health problems showed signs of liver injury and died after receiving the CRISPR treatment; after the company added safety measures, the hold was lifted this year. Jonathan Bernstein, a hereditary angioedema expert involved in the lonvo-z trial, said the four-year data are reassuring and could reduce patients’ long-term burden of frequent medication and managing attacks.